Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-05-16 01:01:00 ET Summary Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. Markets were mostly positive in Q1 2024, with the ongoing notable ex...
2024-05-14 13:21:15 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics gains after data for lymphoma therapy ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript ADC Therapeutics SA 2...
2024-05-14 09:00:16 ET More on Sarepta Therapeutics Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts HHS pa...
2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...
2024-05-11 06:50:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...
2024-05-10 14:13:46 ET More on Alphabet, Recursion, etc. Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript Bronte Capital - Alphabet: Could Not Find Anything We Liked More Google: The Recent Surge Is Far From Over CrowdStrike, Google exp...
2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...
2024-05-08 12:01:57 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investible candidates that may b...
2024-05-07 16:16:50 ET More on Pfizer, Sarepta Pfizer: Solid Earnings, But We're Not Out Of The Woods Yet Pfizer: Ignore The Dead Cat Bounce Pfizer Stock: Finally The Market Is Waking Up Pfizer hires Citi healthcare analyst Baum to lead strategy and innovatio...
2024-05-06 09:50:37 ET Summary Regeneron is not having a great start to 2024 as the company missed Q1 revenue and EPS estimates and received two complete response letters from the FDA for odronextamab. First quarter results were negatively impacted by lower-than-expected collabora...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...